Intercell AG

euro adhoc: Intercell AG
Financial Figures/Balance Sheet
Approvals for Japanese Encephalitis vaccine in U.S., Europe and Australia on track for 2008 - All development programs progressing according to plan - Profitability expected for full year ...

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

9-month report

11.11.2008

Intercell successfully advanced parallel regulatory processes in all key markets for travelers and military personnel - Vaccine against Japanese Encephalitis expected to obtain market approval in the U.S., Europe and Australia in 2008 - U.S. Defense Logistics Agency Request for Proposal (RFP) for purchase of Japanese Encephalitis (JE) vaccine for U.S. military in negotiation

» United States: On October 20, the U.S. Food and Drug Administration (FDA) gave positive feedback on Intercell's application to market its vaccine against Japanese Encephalitis; Intercell and the agency are working    towards the earliest possible approval - ACIP meeting discussion on future    recommendation of JE vaccine held on October 22/23 with formal decision    expected at the February 2009 meeting

» Europe: Approval process advancing according to plan - Intercell expects a    positive opinion from EMEA in December 2008

» Australia: Positive approval decision is expected in December 2008

» Intercell has geared up manufacturing efforts to ensure timely product    delivery to the U.S. military by the end of 2008 and for commercial product    launch in the United States, Europe and Australia in early 2009

Integration of recent acquisition of IOMAI successfully implemented - Focus now on aggressively progressing Travelers' Diarrhea patch vaccine and leveraging patch-based products and technologies

» Strategic focus on late-stage development and industrialization of the    Travelers' Diarrhea patch vaccine and Pandemic Influenza patch vaccine. In    addition, investigation of the use of the patch technology in new vaccine    applications has been effectively initiated

» Start of pivotal Phase III for Travelers' Diarrhea patch vaccine expected    in H1 2009

» Start of Phase II Pandemic flu vaccine expected in H1 2009

Nosocomial infections - S. aureus vaccine and Pseudomonas vaccine progressing in clinical programs - All other development programs and partnerships on track

» Pseudomonas: Start of clinical Phase II/III trials in ventilated Intensive    Care Unit patients expected in December 2008

» S. aureus: Phase II study by Intercell's partner Merck & Co. Inc. in    cardiothoracic surgery progressing well with efficacy data expected by mid    2009 - further Phase II study initiated in hemodialysis patients with late-    stage kidney disease, expanding the field of application of the vaccine

» Pneumococcus: After full preparation of clinical strategy, start of clinical    Phase I trials planned for early 2009

Results from 6-month follow-up of Intercell's therapeutic Hepatitis C vaccine showed statistically significant and long-term antiviral effect in Phase II patients

» Intercell is currently examining options for future development including    the formulation of the vaccine with IC31® and combination with other    antiviral therapies

Therapeutic Monoclonal Antibodies

» Strategic partnering process initiated to extract maximum value out of this    franchise and to keep internal focus on vaccines

Financial Statements

» Intercell's aggregate revenues doubled from EUR 12.6 m in the 9 months ended    September 30, 2007 to EUR 25.3 m in the same period of 2008

» Intercell's net loss decreased by EUR 8.3 m, or 37.6 percent, to EUR 13.8 m    in the first 9 months of 2008 from EUR 22.1 m in the same period of 2007

» As of September 30, 2008 Intercell had liquid funds of EUR 209.0 m, of which    EUR 49.1 m was cash and EUR 159.9 m was available-for-sale financial assets

» Cash preservation is the principal goal of Intercell's short-term cash    management strategy. The impact of the current conditions in the capital    markets on the cash portfolio is therefore minimal

KEY FIGURES - FINANCIAL HIGHLIGHTS

EUR in thousands        3 months ended        9 months ended        Year ended
                                Sept 30,  Sept 30  Sept 30  Sept 30,        Dec 31,
                                 2008         2007        2008        2007              2007

Revenues                  7,641         7,375    25,283    12,559          53,349
Net profit/loss      (5,140)      (6,514) (13,789) (22,085)          5,009
Net operating
profit/loss          24,956      (12,978)      (430) (27,480)         41,686

Cash and market-
able securities,
end of period      208,952      218,580  208,952  218,580         284,571

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Index:    ATX Prime, ATX
Börsen:  Wiener Börse AG / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: